Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is a publicly traded Healthcare sector company. As of May 21, 2026, RXRX trades at $2.96 with a market cap of $1.53B and a P/E ratio of -2.04. RXRX moved +4.04% today. Year to date, RXRX is -32.27%; over the trailing twelve months it is -34.95%. Its 52-week range spans $2.77 to $12.36. Analyst consensus is buy with an average price target of $7.38. Rallies surfaces RXRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes RXRX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $2.96 |
| Market Cap | $1.53B |
| P/E Ratio | -2.04 |
| EPS | $-1.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.36 |
| 52-Week Low | $2.77 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $74.68M |
| Net Income | $-644.76M |
| Gross Margin | 4.99% |
5 analysts cover RXRX: 0 strong buy, 2 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.38.